Overview
Oral Pyrophosphate Absorption in PXE Disease
Status:
Withdrawn
Withdrawn
Trial end date:
2021-04-01
2021-04-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Pyrophosphate is an endogenous, non-toxic metabolite inhibiting soft tissue calcification. The aim of our study is to find optimal dosing and safety of oral disodium-PPi (Na2H2PPi). Absorption curves (pharmacokinetics), AUC0-t, Cmax and Tmax for PPi and phosphate will be provided for healthy controls and PXE-patients both fasting and with standard meal intake.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Tampere University HospitalCollaborators:
Hungarian Academy of SciencesUMC Utrecht
Criteria
Inclusion Criteria:- Adults (>18 yrs)
- clinically and genetically proven PXE
- Body mass index (BMI) 18,5-34,9 kg/m2
Exclusion Criteria:
- Special groups according to researchers' decision.
- Pregnancy
- No effective contraception in females in child-bearing age.